Sorrento, the richest pharmaceutical company in the world, joins hands with Chinese enterprises to enter into biological analogues

Source: e-medicine Facebook 2015-8-5 this article is compiled from the dynamic situation of Huang Xinxiang, the richest Chinese American, who has always been the focus of attention Recently, Sorrento, a biological company invested by him, announced that he would soon cooperate with mabtech (which established the Taizhou mabotaco pharmaceutical industry in China) to acquire the rights and interests of four late stage biological analogues in North America, Europe and Japan Four antibody drugs are currently in phase III, and the original research drugs are all heavyweight drugs that will lose patent protection soon Sorrento said that the four drugs have entered the clinical phase III in China, but Sorrento did not disclose the specific price of the cooperation, only that the total revenue of the four drugs in 2014 was 13 billion US dollars In December 2014, Sorrento and immunooncology company conkwest reached an agreement on jointly developing an immunotherapy scheme for cancer and infectious diseases At present, Sorrento is still looking for more extensive cancer immunotherapy Sorrento's trading strategy is different from that of other biological companies under Huang Xinxiang Its partners are usually compatriots Sorrento hopes to explore a new drug development route in this way "We are looking forward to this cooperation and hope to develop and deepen our product structure," said Henry Ji, CEO of Sorrento "Through this cooperation, Sorrento has taken an important step towards becoming a major member of the biopharmaceutical industry." For Sorrento, the partnership with Chinese companies will expand the company's R & D strategy and focus on cancer immunotherapy Since its establishment, Sorrento has been engaged in whirlwind trading and cooperation, making use of Huang Xinxiang's advantages to carry out asset swap with other companies under its control, and carrying out a variety of R & D projects So far, Sorrento's stock price has tripled.